STE logo

STERIS plc Stock Price

NYSE:STE Community·US$20.2b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 14 Fair Values set on narratives written by author

STE Share Price Performance

US$207.56
-33.78 (-14.00%)
US$256.86
Fair Value
US$207.56
-33.78 (-14.00%)
19.2% undervalued intrinsic discount
US$256.86
Fair Value
Price US$207.56
AnalystConsensusTarget US$256.86

STE Community Narratives

·
Fair Value US$256.86 19.2% undervalued intrinsic discount

Healthcare Demand And Facility Expansion Will Create Value

0users have liked this narrative
0users have commented on this narrative
7users have followed this narrative
US$256.86
19.2% undervalued intrinsic discount
Revenue
6.58% p.a.
Profit Margin
14.54%
Future PE
28.82x
Price in 2029
US$317.01

Trending Discussion

Updated Narratives

STE logo

STE: Share Repurchases And Earnings Outlook Will Support Future Upside

Fair Value: US$256.86 19.2% undervalued intrinsic discount
7 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Solid track record with excellent balance sheet and pays a dividend.

1 Risk
4 Rewards

STERIS plc Key Details

US$5.9b

Revenue

US$3.3b

Cost of Revenue

US$2.6b

Gross Profit

US$1.8b

Other Expenses

US$782.3m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
8.03
44.24%
13.18%
26.8%
View Full Analysis

About STE

Founded
1985
Employees
17937
CEO
Daniel Carestio
WebsiteView website
www.steris.com

STERIS plc provides infection prevention products and services in the United States, Ireland, and internationally. It operates through three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. The company offers cleaning chemistries and sterility assurance products, automated endoscope reprocessing system and tracking products, endoscopy accessories, instruments, washers, and sterilizers and other pieces of capital equipment, as well as equipment used directly in the procedure rooms, including surgical tables, lights, equipment management services, and connectivity solutions; and various preventive maintenance programs, repair services, custom process improvement consulting, and outsourced instrument sterile processing, as well as instrument, devices, and endoscope repair and maintenance services. It also provides process controls and monitoring systems, as well as integrated sterilization equipment, such as accelerators, product handling, and automation; and sterilization modalities, product development, materials testing, and process validation, as well as support services for sterilization equipment and control systems comprising installation, preventive maintenance, updates, repairs, and troubleshooting. In addition, the company offers pharmaceutical detergents, cleanroom disinfectants and sterilants, pharmaceutical grade and research sterilizers and washers, sterility assurance and maintenance products, vaporized hydrogen peroxide room decontamination systems and sterilizers, and high purity water and pure steam generators; and preventive maintenance programs and repair services to support the operation of capital equipment. It serves healthcare providers, medical device and pharmaceutical manufacturers, biopharmaceutical manufacturing facilities, and hospitals. The company was formerly known as New STERIS Limited and changed its name to STERIS plc in November 2015. STERIS plc was founded in 1985 and is headquartered in Mentor, Ohio.

Recent STE News & Updates

Seeking Alpha Jun 09

Steris: Stable, Steady And Appealing

Summary Steris now trades at the low end of its $200–$250 range, with improved earnings and reduced leverage making valuations more attractive. Steris delivered nearly 9% revenue growth to $5.94B, with all segments contributing and organic growth at 7%, though Q4 growth slowed to 5%. Forward guidance targets $11.10–$11.30 EPS on 6–7% organic growth, with leverage at 1x and significant capacity for M&A or capital return. Steris' stable organic growth, reasonable 18–19x forward earnings multiple, and potential for larger M&A enhance its appeal amid sector headwinds. Read the full article on Seeking Alpha

Recent updates

No updates